Albuquerque, NM, United States of America

David S Peabody

This inventor holds 13 USPTO granted patents and 14 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: The University of New Mexico, Sandia Corporation, Johns Hopkins University. Active years: 2015-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David S Peabody. Retrieved from https://idiyas.com/inventor/david-s-peabody

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13 (Patent Applications = 14)

% Patents Active = 100.0

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 3.3

ph-index = 2

Forward Citations = 46(Granted Patents)

Company Filing History:

13 out of 943

The University of New Mexico

Johns Hopkins University

where one patent can have more than one assignee

Years Active: 2015-2024

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12161710 - Malaria immunogen and methods for using same (2024-12-10),

2. 12121574 - Malaria immunogen and methods for using same (2024-10-22),

3. 10821167 - VLP-based vaccines for targetingsecreted virulence factors (2020-11-03),

4. 9943580 - Malaria vaccine (2018-04-17),

5. 9884107 - Immunogenic respiratory syncytial virus glycoprotein-containing VLPs and related compositions, constructs, and therapeutic methods (2018-02-06),

6. 9803189 - Virus-like platform for rapid vaccine discovery (2017-10-31),

7. 9717783 - Immunogenic HPV L2-containing VLPs and related compositions, constructs, and therapeutic methods (2017-08-01),

8. 9549976 - Affinity selection of Nipah and Hendra virus-related vaccine candidates from a complex random peptide library displayed on bacteriophage virus-like particles (2017-01-24),

9. 9533057 - Immunogenic HPV L2-containing VLPs and related compositions, constructs, and therapeutic methods (2017-01-03),

10. 9511135 - Immunogenic respiratory syncytial virus glycoprotein-containing VLPs and related compositions, constructs, and therapeutic methods (2016-12-06),

11. 9480653 - Protocells and their use for targeted delivery of multicomponent cargos to cancer cells (2016-11-01),

12. 9365831 - Plasmids and methods for peptide display and affinity-selection on virus-like particles of RNA bacteriophages (2016-06-14),

13. 8992984 - Protocells and their use for targeted delivery of multicomponent cargos to cancer cells (2015-03-31),

Title: The Innovative Mind of David S. Peabody

Introduction

David S. Peabody, an accomplished inventor based in Albuquerque, NM, has made significant contributions to the field of immunology with a particular focus on combating malaria. With a total of 13 patents to his name, Peabody has showcased his dedication to innovation and the application of scientific research to address pressing health issues.

Latest Patents

Peabody's latest patents revolve around the development of a malaria immunogen, which aims to provide an effective treatment for the disease. One such patent describes an immunogen that includes an immunogenic carrier partnered with an antigenic malaria circumsporozoite protein (CSP) peptide. This specific peptide, NPDPNANPNVDPNAN, comprises amino acids 5-19 of SEQ ID NO:1 and is intended for administration to subjects who have or are at risk of contracting malaria. Another recent patent also focuses on a similar immunogen, utilizing the peptide NANPNVDPNANPNVD (SEQ ID NO:2). This innovation highlights the potential of combination treatment therapies for those experiencing blood stage parasitemia.

Career Highlights

Throughout his career, Peabody has been associated with prominent organizations such as STC.UNM and Sandia Corporation. His work has consistently aimed at leveraging scientific breakthroughs to improve public health, particularly through his advancements in vaccine development and immunotherapy.

Collaborations

David S. Peabody has collaborated with notable colleagues, including Bryce Chackerian and Carlee Erin Ashley, enhancing his research efforts and contributing to the development of innovative solutions for malaria treatment. These partnerships underline the importance of teamwork in the pursuit of scientific excellence.

Conclusion

In conclusion, David S. Peabody's work has paved the way for advancements in malaria treatment through his innovative immunogen patents. His dedication to addressing global health challenges positions him as a leading figure in the field of immunology, and his collaborations further amplify the impact of his contributions. As research continues to evolve, Peabody's inventions may play a pivotal role in the fight against malaria and beyond.

Profile summary based on public USPTO records.